175,423 Shares in Alphatec Holdings, Inc. $ATEC Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH initiated a new stake in Alphatec (NASDAQ:ATEC), acquiring 175,423 shares worth about $3.69 million and representing roughly 0.12% ownership per its latest 13F filing.
• Company insiders have been net sellers: COO Scott Lish sold 260,535 shares (~$3.20M) and General Counsel Tyson Marshall sold 88,835 shares (~$1.11M); insiders disposed of 726,972 shares (~$9.18M) last quarter and now own about 22.8% of the stock.
• Alphatec beat quarterly expectations, reporting $0.06 EPS versus $0.04 expected and revenue of $212.93M (up 20.4% YoY); analysts maintain a consensus "Moderate Buy" rating with an average price target of $22.82.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 175,423 shares of the medical technology company's stock, valued at approximately $3,691,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.12% of Alphatec as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new stake in Alphatec during the third quarter worth approximately $34,000. Osterweis Capital Management Inc. acquired a new stake in Alphatec during the second quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in Alphatec during the third quarter worth approximately $73,000. FNY Investment Advisers LLC acquired a new stake in Alphatec during the third quarter worth approximately $74,000. Finally, State of Alaska Department of Revenue acquired a new stake in Alphatec during the third quarter worth approximately $120,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Insider Buying and Selling at Alphatec

In other news, COO Scott Lish sold 260,535 shares of the firm's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $12.30, for a total value of $3,204,580.50. Following the transaction, the chief operating officer owned 815,704 shares of the company's stock, valued at approximately $10,033,159.20. This trade represents a 24.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the firm's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the completion of the transaction, the general counsel directly owned 559,459 shares in the company, valued at approximately $6,987,642.91. This represents a 13.70% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 726,972 shares of company stock worth $9,184,386. 22.80% of the stock is currently owned by insiders.

Alphatec Stock Performance

NASDAQ:ATEC opened at $9.30 on Thursday. The company has a quick ratio of 1.28, a current ratio of 2.06 and a debt-to-equity ratio of 40.35. The company has a market cap of $1.41 billion, a P/E ratio of -9.79 and a beta of 1.12. Alphatec Holdings, Inc. has a fifty-two week low of $9.15 and a fifty-two week high of $23.29. The firm's 50 day moving average is $11.86 and its two-hundred day moving average is $15.99.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. The company had revenue of $212.93 million for the quarter, compared to analysts' expectations of $212.67 million. The business's revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.23) EPS. Analysts expect that Alphatec Holdings, Inc. will post -0.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Piper Sandler restated an "overweight" rating on shares of Alphatec in a research report on Wednesday, February 25th. Barclays raised their target price on shares of Alphatec from $23.00 to $27.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 7th. Stifel Nicolaus decreased their target price on shares of Alphatec from $24.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday, March 9th. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Alphatec in a research report on Monday, January 12th. Finally, Lake Street Capital reaffirmed a "buy" rating on shares of Alphatec in a research note on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Alphatec presently has a consensus rating of "Moderate Buy" and an average price target of $22.82.

Alphatec Company Profile

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

Want to see what other hedge funds are holding ATEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.